User:Szl313/sandbox

Administration
Entecavir should be taken on an empty stomach, at least 2 hours before a meal or 2 hours after a meal.

Adverse Effects
The most common adverse effects from entecavir include headache, fatigue, dizziness, and nausea. Others adverse effects include diarrhea, dyspepsia, vomitting, somnolence and insomnia. Laboratory abnormalities resulting from treatment include elevated alanine transaminase (ALT) and hematuria. Periodic monitoring of hepatic function and hematology are recommended.

Patent Information
Bristol-Myers Squibb is currently the drug patent holder for Baraclude®, the brand name of entecavir in the US and Canada. The drug patent expiration date for both Baraclude® 0.5 mg and 1 mg tablets is set for February 21, 2015. On August 26, 2014, TEVA Pharms USA gained FDA approval for generic equivalents of Baraclude® 0.5 mg and 1 mg tablets.